Neurosetta, founded in Madison, Wisconsin, is a medical organization dedicated to advancing the understanding of early human brain and spinal cord development through the use of human stem cell-derived platforms. Their core mission is to provide quantitative high-throughput modeling that aids in the study and treatment of neurological conditions. Neurosetta offers a range of products, including RosetteArray® plates for both forebrain and spinal cord research, available in various well formats. Their market focus is primarily on researchers and institutions involved in neurodevelopmental studies and drug discovery.

Notable affiliated individuals include Amy Oler, who plays a significant role in the company's operations. Neurosetta has garnered attention for its innovative RosetteDetect™ image processing technology, which enhances the accuracy and efficiency of their modeling platforms. The company's key achievements include developing protocols and documentation that have become essential resources for the scientific community. Overall, Neurosetta's impact lies in its contribution to more precise and scalable research methodologies, potentially accelerating breakthroughs in understanding and treating neurological disorders.